Kerry J Savage Selected Research

Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)

10/2022	Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
11/2021	Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma.
1/2019	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
1/2018	Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
10/2017	Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.
1/2017	Defining the clonality of peripheral T cell lymphomas using RNA-seq.
2/2016	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
4/2014	The problem with cyclophosphamide, doxorubicin, vincristine and prednisone for the treatment of peripheral T-cell lymphoma.
6/2013	Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
1/2013	Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kerry J Savage Research Topics

Disease

32	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 02/2005
30	Neoplasms (Cancer) 01/2021 - 12/2004
24	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022 - 01/2005
23	Lymphoma (Lymphomas) 10/2022 - 02/2005
17	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 10/2022 - 01/2008
11	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 08/2005
10	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2021 - 12/2006
9	Melanoma (Melanoma, Malignant) 01/2021 - 06/2008
8	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 10/2022 - 02/2005
7	Disease Progression 10/2019 - 05/2007
6	T-Cell Lymphoma (Lymphoma, T Cell) 11/2021 - 01/2008
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 11/2014
4	Neutropenia 10/2018 - 09/2016
3	Febrile Neutropenia 01/2022 - 02/2016
3	Exanthema (Rash) 10/2019 - 09/2016
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2022 - 11/2020
2	Fatigue 09/2016 - 01/2015
1	Uveal melanoma 01/2022
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Second Primary Neoplasms (Neoplasms, Second) 01/2022
1	Vitiligo 01/2022
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 12/2021
1	Sclerosis 10/2021
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021
1	Fever (Fevers) 01/2021
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2017
1	Breast Neoplasms (Breast Cancer) 01/2017
1	Sudden Death 01/2017

Drug/Important Bio-Agent (IBA)

22	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2022 - 09/2012
21	Rituximab (Mabthera)FDA Link 01/2022 - 09/2009
15	Brentuximab VedotinIBA 01/2022 - 06/2012
13	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 10/2012
13	Vincristine (Oncovin)FDA LinkGeneric 10/2022 - 10/2012
13	Dacarbazine (DIC)FDA LinkGeneric 01/2022 - 01/2010
12	Prednisone (Sone)FDA LinkGeneric 10/2022 - 10/2012
10	NivolumabIBA 01/2022 - 01/2015
9	Vinblastine (Vinblastine Sulfate)FDA Link 01/2022 - 09/2012
9	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 09/2012
6	LigandsIBA 10/2018 - 03/2011
5	Bendamustine Hydrochloride FDA Link 01/2022 - 01/2018
5	RNA (Ribonucleic Acid)IBA 01/2022 - 03/2011
5	Biological ProductsIBA 01/2021 - 12/2004
5	Anaplastic Lymphoma KinaseIBA 06/2013 - 07/2009
4	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
4	ParaffinIBA 01/2022 - 09/2015
4	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 02/2015
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2005
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 01/2017
3	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 01/2017
3	IpilimumabIBA 01/2022 - 01/2015
3	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 06/2015
3	Methotrexate (Mexate)FDA LinkGeneric 10/2019 - 06/2015
3	Pharmaceutical PreparationsIBA 01/2019 - 09/2016
3	Formaldehyde (Formol)FDA Link 11/2017 - 09/2015
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022 - 01/2018
2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 06/2015
2	CTLA-4 AntigenIBA 12/2021 - 01/2017
2	AnthracyclinesIBA 01/2021 - 01/2011
2	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2019 - 01/2017
2	Monoclonal AntibodiesIBA 10/2019 - 01/2017
2	Guanosine Diphosphate (GDP)IBA 01/2019 - 01/2017
2	Gemcitabine FDA Link 01/2019 - 01/2017
2	Lipase (Acid Lipase)FDA Link 10/2018 - 09/2016
2	Biomarkers (Surrogate Marker)IBA 11/2017 - 09/2012
2	R-CHOP protocolIBA 10/2016 - 10/2009
2	10-propargyl-10-deazaaminopterin FDA Link 02/2016 - 03/2011
2	enzastaurinIBA 01/2016 - 05/2007
2	TNF Receptor-Associated Factor 1IBA 01/2007 - 02/2005
1	Messenger RNA (mRNA)IBA 11/2021
1	MicroRNAs (MicroRNA)IBA 11/2021
1	SphingolipidsIBA 11/2021
1	Small Cytoplasmic RNAIBA 10/2021
1	SuspensionsIBA 10/2021
1	NS 11IBA 10/2021
1	trametinibIBA 01/2021
1	TTI-621IBA 01/2021
1	dabrafenibIBA 01/2021
1	AntigensIBA 01/2020
1	ChromatinIBA 01/2019
1	Programmed Cell Death 1 ReceptorIBA 01/2019
1	romidepsin (FK228)FDA Link 01/2019
1	Immunoglobulins (Immunoglobulin)IBA 10/2018
1	B7-H1 AntigenIBA 01/2018
1	ibrutinibIBA 01/2017
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2017

Therapy/Procedure

32	Therapeutics 10/2022 - 01/2008
25	Drug Therapy (Chemotherapy) 06/2021 - 12/2005
8	Radiotherapy 12/2021 - 11/2008
8	Stem Cell Transplantation 01/2019 - 06/2012
2	Transplantation 01/2022 - 06/2015
2	Immunotherapy 01/2022 - 01/2019
2	Combined Modality Therapy 10/2019 - 11/2008
2	Cell Transplantation 10/2018 - 06/2015
2	Hematopoietic Stem Cell Transplantation 06/2015 - 01/2008
1	Radioimmunotherapy 01/2022
1	Contraindications 01/2021
1	Organ Transplantation 01/2020
1	Premedication 01/2017